Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.

@article{Openshaw2004NeurophysiologicalSO,
  title={Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.},
  author={Harry Openshaw and Karen Beamon and Timothy W. Synold and Jeff rey Longmate and Neal E. Slatkin and James H. Doroshow and Stephen Forman and Kim A Margolin and Robert Morgan and Stephen I. Shibata and George Somlo},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 2},
  pages={461-7}
}
PURPOSE To determine if there is a beneficial effect of amifostine in preventing or reducing the neuropathy induced by high-dose paclitaxel. METHODS Breast cancer patients receiving high-dose infusional paclitaxel (725 mg/m(2)/24 h) in combination with doxorubicin (165 mg/m(2)/96 h) and cyclophosphamide (100 mg/kg/2 h; ACT) were studied on two autologous peripheral blood stem cell transplant protocols, one with and one without amifostine (740 mg/m(2) administered over 10 min before and 12 h… CONTINUE READING